Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 1, 2008 Brian Lawler	FDA News Gives Glaxo a Glimmer of Hope Approval is delayed, but new studies won't be needed for Cervarix.
The Motley Fool February 8, 2008 Brian Lawler	Hold on to GlaxoSmithKline This might be a tough year for the big pharma company, but its pipeline makes it a keeper.
The Motley Fool April 28, 2008 Brian Lawler	Glaxo Getting By Weakening currency barely redeems the pharmaceutical's Q1 numbers.
The Motley Fool May 8, 2009 Brian Orelli	Glaxo Goes Head-to-Head on HPV Glaxo's data may not be enough to help Cervarix knock Merck's Gardasil from the top papillomavirus vaccine spot.
The Motley Fool October 28, 2009 Brian Orelli	Saved by Emerging Markets. Sort Of. GlaxoSmithKline's top line looks good, but the bottom is what counts.
The Motley Fool October 23, 2008 Brian Orelli	Glaxo to Competitors: You're Cheaper Than We Are This big pharma has cash and it plans to use it.
The Motley Fool February 4, 2010 Brian Orelli	Glaxo Brings Home the Bacon Swine flu gives GlaxoSmithKline the boost, but how long will it last?
The Motley Fool October 27, 2005 Stephen D. Simpson	A Balanced Attack for Glaxo A broad suite of drugs, a huge sales force, and a solid pipeline make GlaxoSmithKline an appealing pharmaceutical company. The problem for investors is that it's all valued into the stock.
The Motley Fool July 30, 2010 Brian Orelli	It's Hard to Get Excited About 92% Revenue Growth Especially when revenue dropped on a comparable basis.
The Motley Fool November 9, 2006 Brian Lawler	The Best Blue Chip for 2007: GlaxoSmithKline Here's a blue-chip pharma stock for your portfolio.
The Motley Fool October 22, 2008 Brian Orelli	Merck's a Bloated Garbage Heap of Stale Drugs Now Merck is planning on cutting 12% of its workforce in the hopes of saving $4 billion through 2013.
The Motley Fool April 23, 2009 Brian Orelli	Hitting the Patent Cliff Early Glaxo is at the front edge of a patent cliff. But that means that when other drugmakers are hurting a few years down the road, Glaxo should be sitting pretty, seeing the fruits of all those partnerships it's investing in now.
The Motley Fool December 5, 2007 Brian Orelli	Merck Stays Conservative Merck sets the bar low with its 2008 guidance. Is the company being overly cautious?
The Motley Fool July 26, 2007 Brian Lawler	Glaxo Getting Through Avandia Loss Glaxo's earnings aren't hurt by the decline in Avandia sales. When excessive fears start to bring down shares of a drugmaker with good sales-growth potential over the long run, smart investors should see a buying opportunity.
The Motley Fool July 7, 2009 Brian Orelli	Glaxo Missed the Boat The HPV vaccine market is declining before Glaxo can hop aboard.
The Motley Fool July 25, 2008 Brian Lawler	Glaxo Changes Course Will a shift in strategy turn the drugmaker around?
The Motley Fool December 18, 2007 Brian Lawler	Cervarix Won't Save Glaxo Yet The FDA has another delay for this HPV vaccine. The agency has completed its review, but still has questions.
The Motley Fool December 5, 2008 Brian Orelli	Good Luck in 2010, Merck It's not just one problem for Merck, but a whole series of issues that have turned the company into a heap of stale drugs.
The Motley Fool February 14, 2005 Stephen D. Simpson	Glaxo Stays Above the Fray The British drugmaker looks to regain momentum this year. Investors who are comfortable with the general industry risks and are looking for a relatively "clean" pharmaceutical company should do some research on Glaxo shares.
The Motley Fool May 1, 2008 Brian Lawler	Glaxo's Global Growth Gambit The pharmaceutical's new CEO has changes in mind.
The Motley Fool December 31, 2007 Brian Lawler	Big Pharma 2008 Forecast Roundup Investors, take a look at what 2008 has in store for big pharma.
The Motley Fool July 28, 2005 Stephen D. Simpson	Glaxo Keeps It Going Despite missing sales from the depression franchise, Glaxo managed to post respectable quarterly results.
The Motley Fool April 29, 2010 Brian Orelli	Earnings Up 17%, but Here's Why You Should Be Worried One-time sales are no way to run a pharmaceutical business.
The Motley Fool January 31, 2008 Brian Orelli	One Last Look at Pre-Enhance Merck Investors show they care more about Merck's future than its Q4 results.
The Motley Fool October 19, 2009 Brian Orelli	The HPV Vaccine Wars of 2010 Merck and GlaxoSmithKline human papillomavirus vaccines were both approved by the Food and Drug Administration for different indications.
The Motley Fool November 6, 2007 Brian Orelli	Getting Vaccinated Alongside Mom Merck presents data supporting use of its HPV vaccine in older women. The drugmaker may have a tough marketing job ahead of it.
The Motley Fool June 26, 2008 Brian Orelli	The FDA's Latest Victim Merck fails to get its Gardasil vaccine approved to treat older women.
The Motley Fool October 30, 2007 Charly Travers	Winners and Losers in Big Pharma Some drugmakers are hitting a slump, but not all of them. Which ones can still cure what ails your portfolio?
The Motley Fool March 28, 2008 Brian Lawler	Is the Dollar Depressing Drug Companies? The falling dollar means different things to big pharma here and in Europe.
The Motley Fool September 10, 2009 Brian Orelli	The Vanishing Vaccine War And it had such potential to be a bloodbath.
The Motley Fool April 22, 2008 Brian Orelli	Will Merck Make It? Merck releases first-quarter results and says it can meet its previous guidance.
The Motley Fool February 26, 2010 Brian Orelli	A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus.
The Motley Fool April 16, 2009 Brian Orelli	2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing.
The Motley Fool September 25, 2006 Brian Lawler	Merck's Positive Contribution Bad press from Vioxx shouldn't overshadow the company's new offering. Investors, take note.
The Motley Fool February 8, 2006 Stephen D. Simpson	Glaxo: Healthy Drugmaker Glaxo combines a huge sales force, a rich pipeline, and solid returns on capital. This company should get a thorough look from anyone putting new money into the pharma space.
The Motley Fool December 17, 2008 Brian Orelli	A Super-Cheap Call Option GlaxoSmithKline announces it's partnering up with tiny Dynavax Technologies to develop up to four drugs for autoimmune and inflammatory diseases. The pay-if-the-drug-works scheme should pay off.
The Motley Fool November 21, 2008 Brian Orelli	Ligand and Glaxo Like the FDA's Answer Good news arrives for blood-clot buster Promacta.
The Motley Fool October 26, 2006 Brian Lawler	Glaxo's Prescription for Sagging Sales Trading at roughly 32 times its trailing-12-month earnings, and with a solid 2.9% dividend yield, GSK is a fine investment for shareholders patient enough to wait until 2008 for a return to solid revenue growth.
The Motley Fool July 20, 2007 Brian Lawler	Glaxo Heats Up the Vaccine Battle GlaxoSmithKline's cervical cancer vaccine gets a positive recommendation in the EU. Sales could begin in early 2008 and will compete with Gardasil, by rival Merck.
The Motley Fool June 17, 2010 Brian Orelli	Merck Needs to Get Busy While waiting for the FDA to approve the expanded age range, sales of Merck's Gardasil have gone to sleep.
The Motley Fool February 12, 2004 Alyce Lomax	Depressing Year for Glaxo The pharmaceutical giant forecasts three lackluster quarters as copycats attack.
The Motley Fool February 3, 2011 Owain Bennallack	Glaxo Sweetens a Bitter Pill The drugmaker reports a loss, but resumes share buybacks.
The Motley Fool February 3, 2011 Brian Orelli	Get Ready for Merck's Bumpy Ride Long-term earnings guidance gets thrown out the window.
The Motley Fool April 4, 2007 Brian Lawler	GlaxoSmithKline Gets Ready for the Vaccine Wars British pharmaceutical powerhouse GlaxoSmithKline submits a marketing application to the FDA for its HPV vaccine. Investors, take note.
The Motley Fool June 15, 2009 Brian Orelli	Strange Bedfellows GlaxoSmithKline is teaming up with none other than its arch-nemesis, generic-drug maker Dr. Reddy's Laboratories, licensing more than 100 of their brands to sell in emerging markets.
The Motley Fool July 18, 2008 Brian Lawler	Still Liking Gilead, Warts and All Don't look past a few issues, even though Gilead still has a bright future.
The Motley Fool December 17, 2007 Brian Lawler	Glaxo, Exelixis Trade Gifts Glaxo announces that it will take over development of a lead Exelixis drug.
The Motley Fool June 23, 2010 Kris Eddy	Drugmakers Finally Recognize the Next Big Opportunity Drug companies seem to be increasing efforts to address female health problems.
The Motley Fool November 30, 2009 Brian Orelli	Making Money More Efficiently Drug companies shape up, and it shows in their margins.
The Motley Fool April 21, 2005 Stephen D. Simpson	Merck Looks for Soft Landing Despite a tough year, the business isn't falling apart, and the pipeline has some near-term gems. This should give investors reason to expect that better things could be on the way.